Skip to Content
Merck
CN

1.16881

Millipore

Fractogel® EMD TMAE (M)

Synonym(s):

Biochromatography, Fractogel® Ion exchangers, Ion exchanger for LC (Fractogel® TSK/EMD), Fractogel® EMD TMAE (M)

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115711

ligand

(Trimethylammoniumethyl)

Quality Level

description

strong anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)

sterility

sterile (Caustic Stable)

product line

Fractogel®

form

resin

parameter

240 cm/hr flow rate
8 bar max. pressure

matrix active group

methacrylate

mean particle size

40-90 μm

capacity

100 mg binding capacity (BSA/mg of resin)

transition temp

flash point 35 °C (calculated)

density

1.430 g/cm3 at 20 °C

bulk density

1000 kg/m3

application(s)

gene therapy
mAb
recombinant protein

separation technique

anion exchange
strong anion exchange

storage temp.

no temp limit

Looking for similar products? Visit Product Comparison Guide

General description

Strong anion exchange Fractogel® resin featuring the tentacle technology with a trimethylammoniumethyl functional group, for purification of acidic and neutral proteins and peptides from multiple sources, DNA and virus removal, plasmid isolation, vaccine purification, and more

Features and Benefits

Fractogel® EMD TMAE (M) enables:

  • High protein loading conditions resulting in good selectivity and resolution with the tentacle technology
  • Excellent binding to large viruses at increased loading
  • Homogenous binding with high selectivity and purity
  • Reduce operating costs and resin replacement with enduring durability - allowing for multiple cycles of column regeneration and sanitization
  • Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution

Packaging

  • 1.16881.0100: Fractogel® EMD TMAE (M) Resin 100ml
  • 1.16881.0010: Fractogel® EMD TMAE (M) Resin 10ml
  • 1.16881.0500: Fractogel® EMD TMAE (M) Resin 500ml
  • 1.16881.0050: Fractogel® EMD TMAE (M) Resin 50ml
Plastic bottle

Analysis Note

Appearance: Milky turbid suspension, free from impurities (foreign particles)
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 80 - 120 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin

Legal Information

FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Pictograms

Flame

Signal Word

Warning

Hazard Statements

Hazard Classifications

Flam. Liq. 3

WGK

WGK 1

Flash Point(F)

95.0 °F

Flash Point(C)

35 °C


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

See All

Related Content

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service